Pär-Ola Bendahl
Lund University
210 Papers
1.4K Citations
Pär-Ola Bendahl is an academic researcher from Lund University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 48, co-authored 185 publications. Previous affiliations of Pär-Ola Bendahl include Linköping University.
Chat about Author
Papers
Leadership perspectives in multidisciplinary team meetings; observational assessment based on the ATLAS instrument in cancer care.
Jessica Wihl,Linn Rosell,Pär-Ola Bendahl,Camila B.R. De Mattos,Sara Kinhult,Gert Lindell,Fredrik Vult von Steyern,Mef Nilbert,Mef Nilbert +8 more
TL;DR: The ATLAS instrument effectively captures various aspects of MDT leadership and chairing skills and may provide relevant information to prioritize initiatives that support and develop effective teamwork and decision-making during MDT meetings.
Stability of oestrogen and progesterone receptor antigenicity in formalin‐fixed paraffin‐embedded breast cancer tissue over time
TL;DR: Stable ER expression in FFPE tissue archived for up to 40 years is indicated, and there was no time‐dependent difference in ERIHC correlation with other biomarkers (HER2, Ki67) or survival.
Noninvasive Staging of Lymph Node Status in Breast Cancer Using Machine Learning: External Validation and Further Model Development.
Malin Hjärtström,Looket Dihge,Pär-Ola Bendahl,Ida Skarping,Julia Ellbrant,Mattias Ohlsson,Lisa Rydén +6 more
TL;DR: A multilayer perceptron (MLP) model for noninvasive lymph node staging (NILS) in a large population-based cohort and develop and validate an LVI MLP for imputation of missing LVI status to increase the preoperative feasibility of the original NILS model are externally validated.
St Gallen molecular subtypes in screening-detected and symptomatic breast cancer in a prospective cohort with long-term follow-up.
Anna-Karin Falck,Andrada Röme,Mårten Fernö,Hans Olsson,Gunilla Chebil,Pär-Ola Bendahl,Lisa Rydén +6 more
TL;DR: Whether the mode of detection (screening‐detected versus symptomatic) adds prognostic information to the St Gallen molecular subtypes of primary breast cancer, in terms of 10‐year cumulative breast cancer mortality (BCM) is explored.
HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
TL;DR: HER2+ and ER+ breast cancer constituted a subgroup of tumours with poor prognosis in premenopausal breast cancer, whereas no treatment interaction was found between HER2 status and tamoxifen in ER+ tumours.